300181 佐力药业
已收盘 08-25 15:00:00
资讯
新帖
简况
深交所创业板再融资动态数据周报(2026.08.17-2026.08.23)
中金财经 · 14:20
深交所创业板再融资动态数据周报(2026.08.17-2026.08.23)
佐力药业(300181.SZ):灵莲花颗粒获得药物临床试验批准
智通财经 · 08-12
佐力药业(300181.SZ):灵莲花颗粒获得药物临床试验批准
股市必读:佐力药业新发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》
证券之星 · 08-07
股市必读:佐力药业新发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》
佐力药业(300181)披露2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市公告,8月5日股价下跌1.54%
证券之星 · 08-05
佐力药业(300181)披露2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市公告,8月5日股价下跌1.54%
佐力药业(300181)披露向不特定对象发行可转换公司债券募集说明书(上会稿),7月20日股价上涨6.49%
证券之星 · 07-20
佐力药业(300181)披露向不特定对象发行可转换公司债券募集说明书(上会稿),7月20日股价上涨6.49%
7月20日佐力药业涨6.49%,宏利效率混合LOF基金重仓该股
证券之星 · 07-20
7月20日佐力药业涨6.49%,宏利效率混合LOF基金重仓该股
佐力药业涨6.49%,东吴证券二个月前给出“买入”评级
证券之星 · 07-20
佐力药业涨6.49%,东吴证券二个月前给出“买入”评级
7月17日佐力药业跌5.90%,宏利效率混合LOF基金重仓该股
证券之星 · 07-17
7月17日佐力药业跌5.90%,宏利效率混合LOF基金重仓该股
7月14日佐力药业涨5.24%,宏利效率混合LOF基金重仓该股
证券之星 · 07-14
7月14日佐力药业涨5.24%,宏利效率混合LOF基金重仓该股
佐力药业涨5.24%,东吴证券二个月前给出“买入”评级
证券之星 · 07-14
佐力药业涨5.24%,东吴证券二个月前给出“买入”评级
佐力药业:公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份
证券之星 · 07-09
佐力药业:公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份
佐力药业:目前除了灵泽片外,还有灵莲花颗粒
证券之星 · 07-09
佐力药业:目前除了灵泽片外,还有灵莲花颗粒
佐力药业:公司向不特定对象发行可转换公司债券已获深圳证券交易所受理
证券之星 · 07-09
佐力药业:公司向不特定对象发行可转换公司债券已获深圳证券交易所受理
佐力药业:西藏未来多种微量元素注射液资产组交接已完成
证券之星 · 07-09
佐力药业:西藏未来多种微量元素注射液资产组交接已完成
股市必读:佐力药业(300181)6月24日披露最新机构调研信息
证券之星 · 06-25
股市必读:佐力药业(300181)6月24日披露最新机构调研信息
佐力药业最新公告:拟发行不超13.71亿元可转债用于智能化中药大健康工厂等项目
证券之星 · 06-23
佐力药业最新公告:拟发行不超13.71亿元可转债用于智能化中药大健康工厂等项目
6月23日佐力药业涨5.67%,宏利效率混合LOF基金重仓该股
证券之星 · 06-23
6月23日佐力药业涨5.67%,宏利效率混合LOF基金重仓该股
佐力药业涨5.67%,东吴证券一个月前给出“买入”评级
证券之星 · 06-23
佐力药业涨5.67%,东吴证券一个月前给出“买入”评级
股市必读:佐力药业(300181)6月17日董秘有最新回复
证券之星 · 06-18
股市必读:佐力药业(300181)6月17日董秘有最新回复
佐力药业:两款乌灵大健康产品已完成研发
证券之星 · 06-17
佐力药业:两款乌灵大健康产品已完成研发
暂无数据
公司概况
公司名称:
浙江佐力药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-02-22
主营业务:
浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵胶囊、灵泽片、灵莲花颗粒、百令片、百令胶囊、三七粉、川贝粉、灵芝孢子粉、聚卡波非钙片/颗粒、多种微量元素注射液(Ⅰ)。公司荣获“全国文明单位”“国家级绿色工厂”“浙江省知名商号”“浙江省重合同、守信用AAA级企业”“2023年度中国中药企业TOP100排行榜”“2023年度浙江省生物医药产业领军型企业”“2023-2024年度赋能县域医疗高质量发展卓越品牌企业”“2024年度最佳ESG管理上市公司”“2025中国中成药企业综合竞争力50强”“2025中国中药研发实力前50强”等称号和荣誉。
发行价格:
23.50
{"stockData":{"symbol":"300181","market":"SZ","secType":"STK","nameCN":"佐力药业","latestPrice":14.08,"timestamp":1787641425000,"preClose":13.98,"halted":0,"volume":10753794,"delay":0,"changeRate":0.0072,"floatShares":603000000,"shares":701000000,"eps":0.9273,"marketStatus":"已收盘","change":0.1,"latestTime":"08-25 15:00:00","open":13.9,"high":14.11,"low":13.84,"amount":151000000,"amplitude":0.0193,"askPrice":14.09,"askSize":1189,"bidPrice":14.08,"bidSize":334,"shortable":0,"etf":0,"ttmEps":0.9273,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":5,"adr":0,"adjPreClose":13.98,"symbolType":"stock","openAndCloseTimeList":[[1787621400000,1787628600000],[1787634000000,1787641200000]],"highLimit":15.38,"lowLimit":12.58,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":701387335,"isCdr":false,"pbRate":2.86,"roa":"--","peRate":15.183867,"roe":"6.09%","epsLYR":0.92,"committee":-0.097929,"marketValue":9876000000,"turnoverRate":0.0178,"status":0,"floatMarketCap":8489000000},"requestUrl":"/m/hq/s/300181/tweets","defaultTab":"tweets","newsList":[{"id":"2662789590","title":"深交所创业板再融资动态数据周报(2026.08.17-2026.08.23)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662789590","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662789590?lang=zh_cn&edition=full","pubTime":"2026-08-25 14:20","pubTimestamp":1787638801,"startTime":"0","endTime":"0","summary":"览富财经网讯:据深交所官网披露,2026 年 8 月 17 日至 8 月 23 日期间,深交所创业板再融资市场保持活跃,共有 12 家企业的再融资项目迎来关键节点,涵盖受理、问询、审核通过、注册生效及终止等多个环节,合计拟募资金额约 126.34 亿元。受理环节方面,本周共有 4 家企业获受理。问询环节方面,恒勃股份、温州宏丰2 家企业收到问询函。此外,商络电子、泰林生物2 家企业可转债项目终止(撤回),分别拟募资 10 亿元、2.3 亿元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/25/20260825779922.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/25/20260825779922.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260825/32346097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300991","BK0224","BK0250","BK0264","BK0039","BK0146","BK0251","BK0042","BK0078","BK0214","BK0061","BK0024","301116","BK0239","BK0046","300283","300048","BK0028","BK0238","300018","301018","BK0102","BK0005","300975","301225","BK0014","BK0077","300093","300181","BK0114","BK0235","BK0130","300397"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658785469","title":"佐力药业(300181.SZ):灵莲花颗粒获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658785469","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658785469?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:51","pubTimestamp":1786524709,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佐力药业 发布公告,公司于近日收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意公司已上市产品灵莲花颗粒开展新增功能主治的临床试验研究。经审查,2026年06月01日受理的灵莲花颗粒临床试验申请符合药品注册的有关要求,在进一步完善临床试验方案的基础上,同意本品开展用于围绝经期综合征伴焦虑状态心肾不交证的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","BK0042","PSYK","BK0077","IBBQ","BK0239","MDTX","BMED","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659672","title":"股市必读:佐力药业新发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659672","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657659672?lang=zh_cn&edition=full","pubTime":"2026-08-07 01:22","pubTimestamp":1786036934,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,佐力药业报收于13.99元,下跌0.85%,换手率3.12%,成交量18.84万手,成交额2.63亿元。公司公告汇总:佐力药业完成2024年限制性股票激励计划预留授予部分第一个归属期登记,归属股票30万股,占总股本0.04%,归属价格7.13元/股,公司层面2025年净利润同比增长31.97%。本次归属不设限售期,公司总股本不变,不影响股权结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700001601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523806","title":"佐力药业(300181)披露2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市公告,8月5日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523806","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523806?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:20","pubTimestamp":1785939626,"startTime":"0","endTime":"0","summary":"近日,浙江佐力药业股份有限公司发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》。公告显示,公司于2026年8月5日完成2024年限制性股票激励计划预留授予部分第一个归属期的归属登记,本次归属激励对象共8人,归属股票数量为30万股,占公司总股本的0.04%,股票来源为公司从二级市场回购的A股普通股。本次归属不设限售期,公司总股本不变,不影响股权结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","300181","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652291239","title":"佐力药业(300181)披露向不特定对象发行可转换公司债券募集说明书(上会稿),7月20日股价上涨6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652291239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652291239?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:43","pubTimestamp":1784540583,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘,佐力药业报收于14.77元,较前一交易日上涨6.49%,最新总市值为103.59亿元。该股当日开盘13.82元,最高14.98元,最低13.75元,成交额达6.05亿元,换手率为6.91%。近日,浙江佐力药业股份有限公司发布《向不特定对象发行可转换公司债券募集说明书(上会稿)》。公告显示,本次发行已获董事会及股东大会审议通过。公司主体及债券信用等级均为AA,评级展望稳定。本次发行未提供担保。报告期内财务报告经审计,均出具标准无保留意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000027344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","300181","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652299880","title":"7月20日佐力药业涨6.49%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652299880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652299880?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:45","pubTimestamp":1784537121,"startTime":"0","endTime":"0","summary":"证券之星消息,7月20日佐力药业涨6.49%,收盘报14.77元,换手率6.91%,成交量41.67万手,成交额6.05亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为-9.06%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300181","162207","BK0042","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652054296","title":"佐力药业涨6.49%,东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2652054296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652054296?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:45","pubTimestamp":1784537112,"startTime":"0","endTime":"0","summary":"今日佐力药业(300181)涨6.49%,收盘报14.77元。2026年4月30日,东吴证券研究员朱国广,向潇发布了对佐力药业的研报《2025年报&2026一季报点评,乌灵系列稳健增长,“一路向 C”战略持续深化》,该研报对佐力药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为84.97%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长城证券的刘鹏。佐力药业(300181)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652471406","title":"7月17日佐力药业跌5.90%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652471406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652471406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:49","pubTimestamp":1784278196,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日佐力药业跌5.90%,收盘报13.87元,换手率6.19%,成交量37.33万手,成交额5.29亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为0.07%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","162207","BK0042","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175824","title":"7月14日佐力药业涨5.24%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651175824?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:29","pubTimestamp":1784017788,"startTime":"0","endTime":"0","summary":"证券之星消息,7月14日佐力药业涨5.24%,收盘报14.87元,换手率7.11%,成交量42.89万手,成交额6.27亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为-3.73%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0077","300181","162207","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175828","title":"佐力药业涨5.24%,东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651175828?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:29","pubTimestamp":1784017779,"startTime":"0","endTime":"0","summary":"今日佐力药业(300181)涨5.24%,收盘报14.87元。2026年4月30日,东吴证券研究员朱国广,向潇发布了对佐力药业的研报《2025年报&2026一季报点评,乌灵系列稳健增长,“一路向 C”战略持续深化》,该研报对佐力药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为84.97%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长城证券的刘鹏。佐力药业(300181)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650874942","title":"佐力药业:公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2650874942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650874942?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583479,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业07月09日在投资者关系平台上答复投资者关心的问题。这是贵司参股的科济药业,贵司按目前股价已大赚了3亿多?介绍科济药业抗癌?公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份,属于其他权益工具投资,其公允价值变动计入公司其他综合收益。科济药业具体情况请详见其在港交所发布的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02171","BK0239","BK0077","300181","BK0042","002173","BK0236","BK0114","BK1587","BK1585","BK1161","BK1574","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650942809","title":"佐力药业:目前除了灵泽片外,还有灵莲花颗粒","url":"https://stock-news.laohu8.com/highlight/detail?id=2650942809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650942809?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583477,"startTime":"0","endTime":"0","summary":"公司深耕优势领域,聚焦乌灵系列创新中药的研发,目前除了灵泽片外,还有灵莲花颗粒,该品种为国内独家产品、OTC品种;另有多个乌灵系列创新药在研发阶段,其中,灵香片、参灵颗粒处于临床试验阶段,还有其他治疗方向的乌灵系列创新中药正在进行临床前的毒理和药学研究,公司稳步推进“立项一批,临床一批,上市一批”的合理布局,致力于将乌灵系列打造成10个产品的大家庭。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300181","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650428799","title":"佐力药业:公司向不特定对象发行可转换公司债券已获深圳证券交易所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2650428799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650428799?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583476,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问:公司向不特定对象发行可转换公司债券的进展如何?佐力药业回复:您好!公司向不特定对象发行可转换公司债券已获深圳证券交易所受理,审核程序正在积极推进中,公司将根据进展及时履行信息披露义务。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399001","300181","BK0239","BK0042","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650942824","title":"佐力药业:西藏未来多种微量元素注射液资产组交接已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2650942824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650942824?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583475,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司收购西藏未来以及两家全资子公司目前进度如何?佐力药业回复:您好!公司收购的西藏未来多种微量元素注射液资产组不涉及股权,该业务的交接工作已完成,产品核心人员已入职佐力药业,产品上市许可持有人变更登记等工作正在有序推进中。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300181","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646843480","title":"股市必读:佐力药业(300181)6月24日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2646843480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646843480?lang=zh_cn&edition=full","pubTime":"2026-06-25 03:39","pubTimestamp":1782329948,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘,佐力药业报收于13.31元,下跌2.2%,换手率2.99%,成交量18.04万手,成交额2.43亿元。公司于2016年、2018年分别对科济药业进行B轮、Pre-C轮投资,累计投入约1亿元,目前通过二级子公司佐力创新医疗持有科济药业28,385,012股;该投资属其他权益工具投资,公允价值变动计入其他综合收益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500003452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0042","BK0239","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645383808","title":"佐力药业最新公告:拟发行不超13.71亿元可转债用于智能化中药大健康工厂等项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383808","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645383808?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:41","pubTimestamp":1782211269,"startTime":"0","endTime":"0","summary":"佐力药业(300181.SZ)公告称,公司拟向不特定对象发行可转换公司债券,募集资金总额不超过13.71亿元(含本数),扣除发行费用后拟用于智能化中药大健康工厂(一期)、“乌灵+X”产品研发项目及补充流动资金。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300032876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300181","BK0077","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645788169","title":"6月23日佐力药业涨5.67%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645788169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645788169?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:38","pubTimestamp":1782203893,"startTime":"0","endTime":"0","summary":"证券之星消息,6月23日佐力药业涨5.67%,收盘报13.61元,换手率4.44%,成交量26.74万手,成交额3.62亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为-10.25%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300181","162207","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645881694","title":"佐力药业涨5.67%,东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2645881694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645881694?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:38","pubTimestamp":1782203881,"startTime":"0","endTime":"0","summary":"今日佐力药业(300181)涨5.67%,收盘报13.61元。2026年4月30日,东吴证券研究员朱国广,向潇发布了对佐力药业的研报《2025年报&2026一季报点评,乌灵系列稳健增长,“一路向 C”战略持续深化》,该研报对佐力药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为84.97%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长城证券的刘鹏。佐力药业(300181)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644723023","title":"股市必读:佐力药业(300181)6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644723023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644723023?lang=zh_cn&edition=full","pubTime":"2026-06-18 02:11","pubTimestamp":1781719870,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,佐力药业报收于13.04元,下跌0.91%,换手率1.1%,成交量6.63万手,成交额8662.25万元。董秘最新回复投资者: 尊敬的董秘您好 ,公司和浙大开发的大健康饮品从一开始说去年年底推出,现在又半年要过了,一拖再拖,现在产品到了什么程度了。当日关注点交易信息汇总:6月17日主力资金净流出1343.04万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300181","BK0239","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644271134","title":"佐力药业:两款乌灵大健康产品已完成研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2644271134","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644271134?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:18","pubTimestamp":1781684294,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘您好 ,公司和浙大开发的大健康饮品从一开始说去年年底推出,现在又半年要过了,一拖再拖,现在产品到了什么程度了。佐力药业回复:您好!公司的大健康产品国内运营公司佐力大健康(德清)有限公司已设立,产品在澳门的商标注册工作也在进行中,目前两款乌灵大健康产品已完成研发,正在推进品牌定位、目标用户画像、产品包装、生产对接等工作,预计今年上市。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700026860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300181","BK0042","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787643617306,"stockEarnings":[{"period":"1week","weight":-0.0483},{"period":"1month","weight":0.0242},{"period":"3month","weight":0.0285},{"period":"6month","weight":-0.1512},{"period":"1year","weight":-0.2796},{"period":"ytd","weight":-0.1133}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0178},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.064},{"period":"1year","weight":0.0147},{"period":"ytd","weight":-0.0219}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江佐力药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41550人(较上一季度减少1.02%)","perCapita":"14510股","listingDate":"2011-02-22","address":"浙江省湖州市德清县阜溪街道志远北路388号","registeredCapital":"70138万元","survey":" 浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵胶囊、灵泽片、灵莲花颗粒、百令片、百令胶囊、三七粉、川贝粉、灵芝孢子粉、聚卡波非钙片/颗粒、多种微量元素注射液(Ⅰ)。公司荣获“全国文明单位”“国家级绿色工厂”“浙江省知名商号”“浙江省重合同、守信用AAA级企业”“2023年度中国中药企业TOP100排行榜”“2023年度浙江省生物医药产业领军型企业”“2023-2024年度赋能县域医疗高质量发展卓越品牌企业”“2024年度最佳ESG管理上市公司”“2025中国中成药企业综合竞争力50强”“2025中国中药研发实力前50强”等称号和荣誉。","listedPrice":23.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佐力药业,300181,佐力药业股票,佐力药业股票老虎,佐力药业股票老虎国际,佐力药业行情,佐力药业股票行情,佐力药业股价,佐力药业股市,佐力药业股票价格,佐力药业股票交易,佐力药业股票购买,佐力药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}